Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Non-small-cell Lung Cancer With Somatic EGFR Mutations 2Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Head and Neck Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thrombocytosis 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1NSCLC Harboring NRG1 Fusion 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Meningeal Neoplasms 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Docetaxel 56Prednisone 36enzalutamide 25Leuprolide 24Magnetic Resonance Spectroscopy 19Abiraterone Acetate 19bicalutamide 17Radiotherapy 15Goserelin 15abiraterone 12acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11olaparib 9Androgen Antagonists 9gallium 68 PSMA-11 8cabazitaxel 8Radiotherapy, Intensity-Modulated 8Metformin 8Ketoconazole 8Gonadotropin-Releasing Hormone 8Cyclophosphamide 8apalutamide 7Doxorubicin 7luprolide acetate gel depot 6cabozantinib 6Radiosurgery 6Estramustine 6Dexamethasone 6Calcitriol 6Biopsy 6pembrolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Prostatic Neoplasms × Afatinib × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT01320280 2022-07-01

BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer

Universitätsklinikum Hamburg-Eppendorf

Phase 2 Terminated
29 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡